|
1
|
Park S, Koo J, Park HS, Kim JH, Choi SY,
Lee JH, Park BW and Lee KS: Expression of androgen receptors in
primary breast cancer. Ann Oncol. 21:488–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsang JY, Ni YB, Chan SK, Shao MM, Law BK,
Tan PH and Tse GM: Androgen receptor expression shows distinctive
significance in ER positive and negative breast cancers. Ann Surg
Oncol. 21:2218–2228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loibl S, Müller BM, von Minckwitz G,
Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A,
Fissler-Eckhoff A, Gerber B, et al: Androgen receptor expression in
primary breast cancer and its predictive and prognostic value in
patients treated with neoadjuvant chemotherapy. Breast Cancer Res
Treat. 130:477–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He J, Peng R, Yuan Z, Wang S, Peng J, Lin
G, Jiang X and Qin T: Prognostic value of androgen receptor
expression in operable triple-negative breast cancer: A
retrospective analysis based on a tissue microarray. Med Oncol.
29:406–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu R, Dawood S, Holmes MD, Collins LC,
Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA and Tamimi
RM: Androgen receptor expression and breast cancer survival in
postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vera-Badillo FE, Templeton AJ, de Gouveia
P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF,
Ocana A and Amir E: Androgen receptor expression and outcomes in
early breast cancer: A systematic review and meta-analysis. J Natl
Cancer Inst. 106:djt3192014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dvinge H, Git A, Gräf S, Salmon-Divon M,
Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al:
The shaping and functional consequences of the microRNA landscape
in breast cancer. Nature. 497:378–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bockhorn J, Yee K, Chang YF, Prat A, Huo
D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, et al:
MicroRNA-30c targets cytoskeleton genes involved in breast cancer
cell invasion. Breast Cancer Res Treat. 137:373–382. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu
M, Tepper CG, Evans CP, Kung HJ and de Vere White RW: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Östling P, Leivonen SK, Aakula A, Kohonen
P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici
D, et al: Systematic analysis of microRNAs targeting the androgen
receptor in prostate cancer cells. Cancer Res. 71:1956–1967. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin PC, Chiu YL, Banerjee S, Park K,
Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB,
Beltran H, et al: Epigenetic repression of miR-31 disrupts androgen
receptor homeostasis and contributes to prostate cancer
progression. Cancer Res. 73:1232–1244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ribas J, Ni X, Haffner M, Wentzel EA,
Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J,
Rodriguez R, et al: miR-21: An androgen receptor-regulated microRNA
that promotes hormone-dependent and hormone-independent prostate
cancer growth. Cancer Res. 69:7165–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ng EK, Li R, Shin VY, Siu JM, Ma ES and
Kwong A: MicroRNA-143 is downregulated in breast cancer and
regulates DNA methyltransferases 3A in breast cancer cells. Tumor
Biol. 35:2591–2598. 2014. View Article : Google Scholar
|
|
17
|
Yan X, Chen X, Liang H, Deng T, Chen W,
Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al: miR-143 and miR-145
synergistically regulate ERBB3 to suppress cell proliferation and
invasion in breast cancer. Mol Cancer. 13:2202014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH,
Liang S, Li B, Li Y, Li D, Wang ED and Liu MF: A novel
miR-155/miR-143 cascade controls glycolysis by regulating
hexokinase 2 in breast cancer cells. EMBO J. 31:1985–1998. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu X, Zhang X, Dhakal IB, Beggs M,
Kadlubar S and Luo D: Induction of cell proliferation and survival
genes by estradiol-repressed microRNAs in breast cancer cells. BMC
Cancer. 12:292012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rasheed SA, Teo CR, Beillard EJ, Voorhoeve
PM, Zhou W, Ghosh S and Casey PJ: MicroRNA-31 controls G protein
alpha-13 (GNA13) expression and cell invasion in breast cancer
cells. Mol Cancer. 14:672015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Augoff K, Das M, Bialkowska K, McCue B,
Plow EF and Sossey-Alaoui K: miR-31 is a broad regulator of
β1-integrin expression and function in cancer cells. Mol Cancer
Res. 9:1500–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sossey-Alaoui K, Downs-Kelly E, Das M,
Izem L, Tubbs R and Plow EF: WAVE3, an actin remodeling protein, is
regulated by the metastasis suppressor microRNA, miR-31, during the
invasion-metastasis cascade. Int J Cancer. 129:1331–1343. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Körner C, Keklikoglou I, Bender C, Wörner
A, Münstermann E and Wiemann S: MicroRNA-31 sensitizes human breast
cells to apoptosis by direct targeting of protein kinase C epsilon
(PKCepsilon). J Biol Chem. 288:8750–8761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Valastyan S, Chang A, Benaich N, Reinhardt
F and Weinberg RA: Concurrent suppression of integrin alpha5,
radixin, and RhoA phenocopies the effects of miR-31 on metastasis.
Cancer Res. 70:5147–5154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ben-Chetrit N, Chetrit D, Russell R,
Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi
H, Koestler WJ, et al: Synaptojanin 2 is a druggable mediator of
metastasis and the gene is overexpressed and amplified in breast
cancer. Sci Signal. 8:ra72015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dobson JR, Taipaleenmäki H, Hu YJ, Hong D,
van Wijnen AJ, Stein JL, Stein GS, Lian JB and Pratap J:
hsa-mir-30c promotes the invasive phenotype of metastatic breast
cancer cells by targeting NOV/CCN3. Cancer Cell Int. 14:732014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shukla K, Sharma AK, Ward A, Will R,
Hielscher T, Balwierz A, Breunig C, Münstermann E, König R,
Keklikoglou I and Wiemann S: MicroRNA-30c-2-3p negatively regulates
NF-κB signaling and cell cycle progression through downregulation
of TRADD and CCNE1 in breast cancer. Mol Oncol. 9:1106–1119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanic M, Yanowsky K, Rodriguez-Antona C,
Andrés R, Márquez-Rodas I, Osorio A, Benitez J and Martinez-Delgado
B: Deregulated miRNAs in hereditary breast cancer revealed a role
for miR-30c in regulating KRAS oncogene. PLoS One. 7:e388472012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bockhorn J, Dalton R, Nwachukwu C, Huang
S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, et al:
MicroRNA-30c inhibits human breast tumour chemotherapy resistance
by regulating TWF1 and IL-11. Nat Commun. 4:13932013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fang Y, Shen H, Cao Y, Li H, Qin R, Chen
Q, Long L, Zhu XL, Xie CJ and Xu WL: Involvement of miR-30c in
resistance to doxorubicin by regulating YWHAZ in breast cancer
cells. Braz J Med Biol Res. 47:60–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yi H, Liang B, Jia J, Liang N, Xu H, Ju G,
Ma S and Liu X: Differential roles of miR-199a-5p in
radiation-induced autophagy in breast cancer cells. FEBS Lett.
587:436–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shatseva T, Lee DY, Deng Z and Yang BB:
MicroRNA miR-199a-3p regulates cell proliferation and survival by
targeting caveolin-2. J Cell Sci. 124:2826–2836. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eades G, Wolfson B, Zhang Y, Li Q, Yao Y
and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in
triple-negative breast cancer via targeting ARF6. Mol Cancer Res.
13:330–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ,
Jiang Y, Chen X, Qi Y, Zhang X, et al: MiR-145 inhibits tumor
angiogenesis and growth by N-RAS and VEGF. Cell Cycle.
11:2137–2145. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng
L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth
through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
|
|
36
|
Spizzo R, Nicoloso MS, Lupini L, Lu Y,
Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, et al:
miR-145 participates with TP53 in a death-promoting regulatory loop
and targets estrogen receptor-alpha in human breast cancer cells.
Cell Death Differ. 17:246–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Götte M, Mohr C, Koo CY, Stock C, Vaske
AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, et al:
miR-145-dependent targeting of Junctional adhesion molecule A and
modulation of fascin expression are associated with reduced breast
cancer cell motility and invasiveness. Oncogene. 29:6569–6580.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu J, Wang X, Yang X, Liu Y, Shi Y, Ren J
and Guleng B: miRNA423-5p regulates cell proliferation and invasion
by targeting trefoil factor 1 in gastric cancer cells. Cancer Lett.
347:98–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ichikawa T, Sato F, Terasawa K, Tsuchiya
S, Toi M, Tsujimoto G and Shimizu K: Trastuzumab produces
therapeutic actions by upregulating miR-26a and miR-30b in breast
cancer cells. PLoS One. 7:e314222012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tong SJ, Liu J, Wang X and Qu LX:
microRNA-181 promotes prostate cancer cell proliferation by
regulating DAX-1 expression. Exp Ther Med. 8:1296–1300.
2014.PubMed/NCBI
|
|
41
|
Nakano K, Miki Y, Hata S, Ebata A, Takagi
K, McNamara KM, Sakurai M, Masuda M, Hirakawa H, Ishida T, et al:
Identification of androgen-responsive microRNAs and
androgen-related genes in breast cancer. Anticancer Res.
33:4811–4819. 2013.PubMed/NCBI
|
|
42
|
Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang
J and Niu Y: Androgen receptor decreases CMYC and KRAS expression
by upregulating let-7a expression in ER−,
PR−, AR+ breast cancer. Int J Oncol.
44:229–237. 2014.PubMed/NCBI
|
|
43
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005.PubMed/NCBI
|
|
44
|
Chang SH, Lu YC, Li X, Hsieh WY, Xiong Y,
Ghosh M, Evans T, Elemento O and Hla T: Antagonistic function of
the RNA-binding protein HuR and miR-200b in post-transcriptional
regulation of vascular endothelial growth factor-A expression and
angiogenesis. J Biol Chem. 288:4908–4921. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oneyama C and Okada M: MicroRNAs as the
fine-tuners of Src oncogenic signalling. J Biochem. 157:431–438.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang
W, Yin Y and Guan X: Antiproliferative effect of androgen receptor
inhibition in Mesenchymal stem-like triple-negative breast cancer.
Cell Physiol Biochem. 38:1003–1014. 2016. View Article : Google Scholar : PubMed/NCBI
|
